Ulrich Mrowietz, MD, is a professor of dermatology at the University Medical Center Schleswig-Holstein in Kiel, Germany.

How Well-Being in Psoriasis is Being Assessed Via WHO-5, With Ulrich Mrowietz, MD

 interview, Ulrich Mrowietz, MD, professor of dermatology at the University Medical Center Schleswig-Holstein in Kiel, Germany, spoke on recently published findings resulting from the POSITIVE study, describing the rising importance of patient-reported outcomes (PROs) in the 

 landscape and within the broader movement toward patient-centered care.

The POSITIVE study, also previously highlighted at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris, was noted by Mrowietz as having been designed as 1 of the first real-world psoriasis studies to implement the World Health Organization-Five Well-Being Index (WHO-5) as its primary endpoint rather than traditional physician-assessed disease measures.

Why WHO-5 is Significant as a Tool for Psoriasis

“POSITIVE…was planned as such to be the first [trial] in the real world evidence-based space where the primary endpoint was not a somatic score, like in psoriasis with PASI or the Physician's Global Assessment, but a patient-reported outcome tool,” Mrowietz said.

Despite his acknowledgement of clinical metrics such as the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) as important, Mrowietz described WHO-5 as capturing a broader concept of well-being among patients given its encompassing of social, psychological, and personal health elements. Given the instrument’s established normative data among general populations across multiple countries, the POSITIVE team were able to compare the well-being of patients with psoriasis directly with that of the general European population.

Mrowietz described one of the study's most striking findings was the degree of improvement observed following treatment with tildrakizumab. Baseline WHO-5 scores were substantially lower than expected, reaching levels comparable to those reported in patients living with other serious chronic illnesses.

By the 16-week mark, however, average well-being scores had risen to levels comparable to those of those in the general European population and continued to see improvement throughout the 2-year study period. These gains paralleled sustained levels of skin clearance, with the majority of those evaluated showing low absolute PASI scores. Such scores were indicative of minimal disease activity.

Outside of patient well-being assessments, the POSITIVE study also examined the effects of psoriasis on family members through the FamilyPsO questionnaire. In his interview, Mrowietz stated that although partner burden improved over the course of the trial, concerns related to disease recurrence often persisted despite long-term disease control. What this essentially suggests, Mrowietz noted, is the psychological impact of chronic inflammatory disease may extend beyond the patient and continue after clinical symptoms have been addressed.

Disclosures: Mrowietz has reported serving as an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of AbbVie, Aditxt, Almirall, Amgen, Aristea, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Dr. Reddy’s, Eli Lilly, Foamix, Formycon, Immunic, Janssen, LEO Pharma, Medac, MetrioPharm, Novartis, Phi-Stone, Pierre Fabre, Sanofi-Aventis, UCB Pharma.

Mrowietz U, Sommer R, Augustin M, et al. Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study. Psoriasis (Auckl). 2026 May 12;16:590189. 

Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025. Almirall, S.A. (ALM). 

https://www.almirall.com/news-media/newsroom/almirall-presents-long-term-results-first-real-world-dermatology-study-using

Videos

This interview highlights both key findings and the significance of the POSITIVE trial for clinicians and for individuals with psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

metabolic dysfunction-associated steatotic liver disease (MASLD)

 continuing to reshape clinical practice. From expert discussions on newly approved therapies to emerging data on disease progression and cardiometabolic risk, the month's developments highlighted the increasingly personalized approach to liver disease management.

Among the notable updates were continued conversations surrounding the historic approval of bulevirtide for chronic hepatitis delta virus infection and the evolving treatment pipeline for HDV. Regulatory momentum also continued in 

, with expert analysis of the Priority Review application for saroglitazar, while new data for the investigational ileal bile acid transporter inhibitor volixibat reinforced its potential to improve symptom burden in primary sclerosing cholangitis (PSC).

Meanwhile, MASLD remained a major focus, with new evidence supporting more comprehensive approaches to disease management. Experts highlighted evolving pharmacologic strategies, emerging biomarkers to identify patients at risk of advanced liver disease, and additional analyses suggesting resmetirom may provide cardiovascular benefits alongside its effects on MASH.

In this hepatology month in review, the editorial team of 

 highlights the key clinical updates, expert perspectives, and research findings that shaped June.

Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline

In the latest episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by guest Tatyana Kushner, MD, to discuss HDV testing gaps, bulevirtide’s historic FDA approval, and the emerging delta hepatitis pipeline.

Saroglitazar Targets Bile Acid Dysregulation, Inflammation in PBC, With Raj Vuppalanchi, MD

Following the FDA Priority Review of the new drug application (NDA) for saroglitazar in PBC, with a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026, Raj Vuppalanchi, MD, discusses the therapy’s mechanism of action and the Phase 2b/3 EPICS-III data supporting the application.

Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care

Volixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, may eventually offer the first FDA-approved therapy specifically targeting cholestatic pruritus in PSC. Full results from the phase 2b VISTAS study evaluating volixibat in patients with PSC were presented at the European Association for the Study of the Liver (EASL) meeting and will eventually support a 2026 NDA.

, Gideon Hirschfield, FRCP, PhD, discussed the data and its implications for patient-centered care in PSC, particularly around symptom burden related to itch and fatigue.

Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care, With Gideon Hirschfield, FRCP, PhD

Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework

While lifestyle intervention remains the foundation of care in MASLD, it is increasingly being recognized that the delivery may be more effective if given as a structured, prescription-like intervention, outsourcing appropriate clinical support. Zobair Younossi, MD, MPH, reviews expanding pharmacologic options for MASLD/MASH and phase 4 EXCEL trial data supporting a multidimensional approach to MASLD treatment outcomes.

Triglyceride-Glucose Index Associated With Risk of End-Stage Liver Disease in MASLD

The triglyceride-glucose (TYG) index, a traditional marker of insulin resistance, may be a useful tool for predicting incident end-stage liver disease in patients with MASLD without diabetes, according to data presented at the 

Endocrine Society (ENDO) Annual Meeting 2026

 in Chicago, Illinois, by Michal Meron, MD, an endocrine fellow at the Albert Einstein College of Medicine, who discussed the findings with 

MAESTRO-NASH: Resmetirom May Reduce Cardiovascular Risk in MASH, With or Without Statins

New data from a secondary analysis of phase 3 MAESTRO-NASH trial suggest resmetirom (Rezdiffra) may reduce cardiovascular risk in patients with MASH by significantly improving multiple atherogenic lipids and lipoproteins, including LDL-C, ApoB, and Lp(a), regardless of baseline statin use. Meena Bansal, MD, breaks down the findings and explains resmetirom's potential to target liver disease and cardiometabolic risk in MASH.

Articles

June’s hepatology developments emphasized increasingly personalized management across viral hepatitis, cholestatic liver disease, and MASLD/MASH. Landmark FDA approval of bulevirtide refocused attention on persistent HDV testing gaps and a rapidly expanding delta pipeline. In cholestatic disease, saroglitazar advanced under FDA Priority Review for PBC, while phase 2b VISTAS data supported volixibat as a symptom-targeted option for PSC-related pruritus and fatigue. MASLD updates highlighted structured lifestyle “prescriptions,” broader pharmacologic strategies, risk stratification using biomarkers, and resmetirom’s potential cardiometabolic benefit.

Catch up on the latest in hepatology, from bulevirtide’s FDA approval for hepatitis delta to expert perspectives on new and emerging therapies in PBC, PSC, and MASLD.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

6 Hepatology Headlines You Missed in June 2026

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The second quarter of 2026 brought continued momentum across nephrology, from landmark regulatory decisions and pivotal phase 3 trial results to advances in precision medicine and evolving approaches to 

 management. The quarter featured the first 

focal segmental glomerulosclerosis (FSGS),

 encouraging long-term data in IgA nephropathy (IgAN), and growing emphasis on earlier intervention and individualized care.

Here are 7 of the biggest nephrology stories from April through June:

On April 13, 2026, the FDA granted full approval to sparsentan for the treatment of FSGS, marking the first approved therapy specifically indicated for the rare glomerular disease. Supported by data from the phase 3 DUPLEX and phase 2 DUET trials, the approval represents a landmark moment for patients and clinicians after decades of reliance on supportive care and off-label immunosuppression.

APPLAUSE-IgAN: Iptacopan Slows Kidney Function Decline

Final 2-year results from the phase 3 APPLAUSE-IgAN trial showed iptacopan reduced the rate of eGFR decline by 49.3% compared with placebo while lowering the risk of kidney failure events by 43%. The findings add to growing evidence supporting complement inhibition as a disease-modifying strategy in IgAN.

FDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD

Based on positive results from the phase 3 FINE-ONE trial, on May 21, 2026, the FDA accepted Bayer's supplemental New Drug Application and granted Priority Review for finerenone in adults with type 1 diabetes and CKD. If approved, the indication would expand treatment options for a population with limited therapies to slow kidney disease progression.

9-Protein Plasma Score Predicts Kidney Failure Risk in APOL1 High-Risk Individuals

Investigators developed and validated a plasma proteomic risk score capable of identifying APOL1 high-risk individuals most likely to progress to kidney failure years before declines in eGFR or increases in albuminuria become apparent. The findings highlight the growing role of biomarkers in earlier risk stratification and precision nephrology.

Rituximab Lowers Relapse Risk in TURING Trial

Kidney Compass: Rituximab Cuts Relapse Risk in MCD, FSGS in TURING Trial

Late-breaking data from the TURING trial presented at ERA 2026 showed rituximab significantly reduced relapse risk in adults with minimal change disease and FSGS. The prospective findings strengthen evidence supporting rituximab as a treatment option for primary glomerular diseases.

To mark IgAN Awareness Day, HCPLive spoke with leading nephrologists about how advances in disease-modifying therapies are reshaping the management of IgAN. Experts discussed earlier diagnosis, evolving treatment sequencing, biomarker development, and a changing definition of remission as the field moves beyond supportive care alone.

The Pillared Approach Continues to Reshape CKD Care

Speaking with HCPLive, Katherine Tuttle discussed how a "pillared approach" to CKD management, integrating RAAS inhibition, SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists, is shifting clinical practice from treating individual risk factors to comprehensively slowing kidney disease progression while reducing cardiovascular risk.

Second-quarter 2026 developments in nephrology highlighted rapid maturation of disease-modifying therapy across glomerular disease and CKD. Full FDA approval of sparsentan established the first on-label option for FSGS, while 2-year APPLAUSE-IgAN data strengthened complement inhibition with substantial attenuation of eGFR decline and fewer kidney-failure events. Regulatory momentum continued with Priority Review for finerenone in type 1 diabetes–associated CKD. Precision nephrology advanced via a proteomic score identifying APOL1 high-risk progressors, alongside prospective evidence supporting rituximab to reduce relapse.

Here are 7 of the biggest nephrology stories from Q2 of 2026!


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

FDA News

Q2 2026 Recap: Nephrology News & Updates

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

The first half of 2026 delivered significant regulatory and clinical momentum across 

expanded lumateperone (Caplyta) for schizophrenia relapse prevention, approved milsaperidone (Bysanti) for bipolar I disorder and schizophrenia, cleared ProlivRx as the first at-home neuromodulation device for major depressive disorder (MDD), and accepted centanafadine's NDA for priority review in ADHD.

Psychedelic-assisted therapy also gained ground. A White House executive order accelerated federal research pathways, while 3 separate pivotal trials reported positive data. DT120 (lysergide), COMP360 psilocybin, and GH001 each showed rapid, durable antidepressant effects in difficult-to-treat 

This half-year recap gathers HCPLive's most notable psychiatry coverage from January through June 2026, spanning new drug approvals, phase 3 trial results, and shifting federal policy on mental health treatment.

FDA Regulatory Roundup: Schizophrenia, Bipolar Disorder, ADHD, and MDD Approvals

FDA Approves Lumateperone sNDA With 63% Relapse Risk Reduction In Schizophrenia

The FDA approved a supplemental New Drug Application for lumateperone (Caplyta, Intra-Cellular Therapies), adding relapse prevention to its schizophrenia indication. Phase 3 Study 304 showed a 63% reduction in relapse risk versus placebo over 26 weeks, with 84% of patients relapse free at 6 months. Christoph U. Correll, MD, of the Zucker School of Medicine at Hofstra/Northwell, said in a statement that relapse often reverses treatment gains and drives hospitalization. Lumateperone is also approved for bipolar depression and adjunctive MDD.

FDA Approves Milsaperidone for Acute Bipolar I Disorder, Schizophrenia

The FDA approved milsaperidone (Bysanti, Vanda Pharmaceuticals), a new atypical antipsychotic and active iloperidone (Fanapt) metabolite, for first-line acute bipolar I mania and adult schizophrenia. Approval leveraged bioequivalence to iloperidone and its existing efficacy database. The drug carries a boxed warning for dementia-related psychosis mortality and requires QTc monitoring, with commercial availability expected in Q3 2026.

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

The FDA approved ProlivRx (Neurolief), the first at-home, physician-directed neuromodulation therapy for MDD unresponsive to antidepressants. The device delivers external combined occipital and trigeminal afferent stimulation (eCOT-AS) through a wearable headset. In the multicenter MOOD trial, led by Linda Carpenter, MD, of Brown University and Butler Hospital, ProlivRx achieved 21.3% remission versus 6.0% for sham.

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

The FDA accepted Otsuka's New Drug Application for centanafadine, a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI), for priority review in pediatric and adult ADHD, with a July 24, 2026, PDUFA date. Four phase 3 trials showed significant ADHD-RS-5 and AISRS improvements across children, adolescents, and adults versus placebo

Psychedelic Momentum: White House Policy and Phase 3 & 2b Data in Depression

White House Order Accelerates Psychedelic Research for Mental Illness, With Gus Alva, MD

A White House executive order directed the FDA and DEA to accelerate psychedelic drug research for serious mental illness, authorizing national priority vouchers, Right to Try access, and > $50 million in state-level research funding. Gus Alva, MD, medical director of ATP Clinical Research, told 

that patient interest in psychedelics reflects an unmet treatment need rather than a trend to dismiss. Alva cautioned that therapist training and clinical infrastructure must keep pace with expanding federal policy.

Emerge Phase 3 Data Show DT120 Lysergide Delivers Rapid, Durable MDD Relief, Says John Sonnenberg, PhD

Definium Therapeutics' phase 3 Emerge trial showed DT120 (lysergide) ODT produced rapid, durable relief in MDD, meeting its primary endpoint with an 8.1-point placebo-adjusted MADRS improvement at week 6. Remission occurred in 24% of patients versus 3% on placebo, with no suicidality signals. Investigator John Sonnenberg, PhD, of Northwestern University Feinberg School of Medicine, said the results confirmed genuine antidepressant efficacy for psychedelics. A second phase 3 study, Ascend, is underway.

COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRD

Compass Pathways' synthetic psilocybin COMP360 met the primary endpoint in its second phase 3 trial, COMP006, for treatment-resistant depression (TRD). Two 25-mg doses, given 3 weeks apart, produced a statistically significant MADRS reduction versus 1-mg control at week 6. Compass Pathways holds FDA Breakthrough Therapy designation and plans a Q4 2026 NDA submission following rolling review discussions with the FDA.

Single-Day GH001 for TRD Shows Rapid Response, With Michael E. Thase, PhD

GH Research's phase 2b trial of inhaled GH001 (mebufotenin) showed rapid, durable relief in treatment-resistant depression, with 57.5% remission by day 8 versus 0% on placebo. Michael E. Thase, MD, of the Perelman School of Medicine at the University of Pennsylvania, called the single-day, individualized dosing regimen a wonderful and clinically meaningful result. The short psychoactive duration, 9 to 14 minutes, allows outpatient administration, with retreatment anticipated roughly every 6 weeks.

Regulatory activity in early 2026 broadened options across schizophrenia, bipolar I disorder, MDD, and ADHD, including relapse prevention labeling for lumateperone, approval of milsaperidone, and clearance of an at-home neuromodulation device for antidepressant-nonresponsive depression. Centanafadine’s priority review signaled potential first-in-class NDSRI entry for pediatric and adult ADHD. Psychedelic therapeutics advanced via federal policy support and late-stage evidence, with lysergide DT120, psilocybin COMP360, and inhaled GH001 showing rapid, durable antidepressant effects in difficult-to-treat populations.

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

First Half 2026 Recap – Psychiatry

, with late-stage clinical trial successes in ulcerative colitis, expanded treatment options for pediatric patients, and expert insights into the diagnosis of complex gastrointestinal disorders. Together, the month's developments highlighted ongoing innovation in 

 while reinforcing the importance of timely recognition and multidisciplinary management across the spectrum of GI care.

Among the most notable updates were positive phase 3 results for the investigational therapies tulisokibart and obefazimod, both of which demonstrated meaningful efficacy in patients with moderately to severely active ulcerative colitis. Tulisokibart became the first anti-TL1A therapy to meet phase 3 endpoints in ulcerative colitis, while obefazimod showed durable remission in a highly refractory patient population, further expanding the pipeline of potential treatment options.

Beyond inflammatory bowel disease, clinicians gained additional perspective on the expanding pediatric indication for linaclotide in functional constipation and the diagnostic challenges posed by conditions such as hereditary angioedema, mast cell activation syndrome, and eosinophilic gastrointestinal disorders that can mimic more common GI conditions.

In this gastroenterology month in review, the editorial team of 

highlights the key clinical trial updates, regulatory developments, and expert perspectives that shaped June.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A

On June 22, 2026, Merck announced positive topline results from the phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active ulcerative colitis. The study successfully met its primary endpoint of clinical remission according to the Modified Mayo Score at week 12 as well as key secondary endpoints, with no new safety concerns identified.

Obefazimod Delivers Week 44 Remission in Refractory UC Patients

On June 29, 2026, Abivax SA announced topline results from ABTECT Maintenance Part 2, the supplemental portion of its phase 3 ulcerative colitis maintenance program evaluating obefazimod, an investigational oral miR-124 enhancer, in adults with moderately to severely active ulcerative colitis. Results showed obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative colitis population, with 37.2% of induction non-responders achieving clinical remission and 34.5% achieving endoscopic remission at week 44 following continued 50 mg treatment.

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation

Following the May 27, 2026, US Food and Drug Administration expanded approval of Ironwood Pharmaceuticals' linaclotide (Linzess) for pediatric patients aged ≥2 years with functional constipation, the editorial team of 

 spoke with Julie Khlevner, MD, a pediatric gastroenterologist at Columbia University Vagelos College of Physicians and Surgeons and an associate professor at Columbia University Medical Center. She spoke on the burden of functional constipation, the data supporting the expanded approval, and what the availability of this treatment means for patient care.

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs

While conditions like hereditary angioedema (HAE), mast cell activation syndrome (MCAS), and eosinophilic GI disorders can all present with episodic abdominal symptoms, they remain low on the radar of most primary care providers and even gastroenterologists seeing these patients first. Brian Lacy, MD, PhD, a board-certified gastroenterologist at the Mayo Clinic in Jacksonville, explained to 

 how he approaches this differential from the gastroenterology side and where collaboration with allergy and immunology becomes essential.

June featured late-stage advances in ulcerative colitis therapeutics alongside notable regulatory and diagnostic developments across gastroenterology. Phase 3 programs for tulisokibart and obefazimod achieved clinically meaningful remission endpoints in moderately to severely active disease, including durable benefit in refractory populations. Pediatric functional constipation management expanded with FDA approval of linaclotide down to age 2 years, broadening pharmacologic options for a high-burden condition. Expert guidance also underscored the need to recognize HAE, MCAS, and EGIDs as episodic abdominal pain mimics requiring multidisciplinary evaluation.

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

4 Gastroenterology Headlines You Missed in June 2026

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

Q2 2026 Recap: Psychiatry News & Updates

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

First Half 2026 Recap - Cardiology

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.

8 Dermatology Headlines You Missed in June 2026

Phase 3 RAPIDe-3 data show rapid, sustained relief of hereditary angioedema attacks; PDUFA date set for April 23, 2027. 

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

FDA Accepts NDA for Oral Deucrictibant for HAE Attacks

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonary Fibrosis

First Half 2026 Recap - Pulmonology

Shannon C. Trotter, DO, is a dermatologist and podcast host from Springfield, Ohio.

This interview segment from SDPA highlights insights on hormonal impacts on dermatology as well as other key highlights from sessions at the meeting.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

What Are the Impacts of Hormones on Skin Health? With Shannon Trotter, DO

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

First Half 2026 Recap - Endocrinology

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

3 Psychiatry Headlines You Missed in June 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Dyslipidemia

9 Cardiology Headlines You Missed in Q2 2026

Andrew Bzowyckyj, PharmD, BCPS, CDCES,  is the senior scientific director of Learning Consulting at the National Kidney Foundation. 

Andrew Bzowyckyj, PharmD, explains the transition to the 2021 CKD-EPI equation and its implications for medication decisions.


Latest News

How Well-Being in Psoriasis is Being Assessed Via WHO-5, With Ulrich Mrowietz, MD

6 Hepatology Headlines You Missed in June 2026

Q2 2026 Recap: Nephrology News & Updates

First Half 2026 Recap – Psychiatry

4 Gastroenterology Headlines You Missed in June 2026